Abstract
Fixed dose combinations of Pantoprazole and Tetracycline (PT) have a wider range of susceptibility than any one of these two drugs individually. The present study was carried out to determine the Minimum Inhibitory Concentration (MIC) and Time kill curve of Pantoprazole, Tetracycline and a fixed dose combination of these two drugs in four groups (HP-B1, HP-B2, HP-B3, HP-B4) of Helicobacter pylori (H. pylori) bacteria. The MIC were found to be 0.03125 mg/l, 0.03125 mg/l, 0.03125 mg/l, and 0.0625 mg/l for PT, 32mg/l, 64mg/l, 32mg/l, 64mg/l, respectively, for Pantoprazole and 0.125 mg/l, 0.125mg/l, 0.125mg/l, and 0.25mg/l for tetracycline, respectively, in the different groups . In all H. pylori groups studied, the time-kill curve analysis demonstrated maximum bacterial killing at 4 hours with PT having the most pronounced effect. From the present findings it can be concluded that a fixed dose combination of pantoprazole and tetracycline has better efficacy and more bacterial inhibiting properties than Pantoprazole or Tetracycline alone.
Keywords: Minimum inhibitory concentration, time kill curve, fixed dose combination, pantoprazole, tetracycline
Current Drug Therapy
Title: Comparative In Vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection
Volume: 4 Issue: 2
Author(s): Dharmendra Rai, Vivek Kumar Dwivedi, Manu Chaudhary, Sanjay Mohan Shrivastava, Praveen Rishi and Pramod Kumar Pandey
Affiliation:
Keywords: Minimum inhibitory concentration, time kill curve, fixed dose combination, pantoprazole, tetracycline
Abstract: Fixed dose combinations of Pantoprazole and Tetracycline (PT) have a wider range of susceptibility than any one of these two drugs individually. The present study was carried out to determine the Minimum Inhibitory Concentration (MIC) and Time kill curve of Pantoprazole, Tetracycline and a fixed dose combination of these two drugs in four groups (HP-B1, HP-B2, HP-B3, HP-B4) of Helicobacter pylori (H. pylori) bacteria. The MIC were found to be 0.03125 mg/l, 0.03125 mg/l, 0.03125 mg/l, and 0.0625 mg/l for PT, 32mg/l, 64mg/l, 32mg/l, 64mg/l, respectively, for Pantoprazole and 0.125 mg/l, 0.125mg/l, 0.125mg/l, and 0.25mg/l for tetracycline, respectively, in the different groups . In all H. pylori groups studied, the time-kill curve analysis demonstrated maximum bacterial killing at 4 hours with PT having the most pronounced effect. From the present findings it can be concluded that a fixed dose combination of pantoprazole and tetracycline has better efficacy and more bacterial inhibiting properties than Pantoprazole or Tetracycline alone.
Export Options
About this article
Cite this article as:
Rai Dharmendra, Dwivedi Kumar Vivek, Chaudhary Manu, Shrivastava Mohan Sanjay, Rishi Praveen and Pandey Kumar Pramod, Comparative In Vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection, Current Drug Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157488509788185196
DOI https://dx.doi.org/10.2174/157488509788185196 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging Editorial [Hot Topic: The Fabisch-Symposium 2009 on Targeted Tumor Therapies(Guest Editors: C. Bachran and H. Fuchs)]
Current Drug Targets Random Mutagenesis Methods for In Vitro Directed Enzyme Evolution
Current Protein & Peptide Science Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Metabolic Fate of Endocannabinoids
Current Neuropharmacology Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies
Current Topics in Medicinal Chemistry 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews